Title

Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

Document Type

Article

Publication Date

10-1-2015

Publication Title

Journal of the American Society of Nephrology : JASN

Abstract

Ferric citrate (FC) is a phosphate binder with shown efficacy and additional effects on iron stores and use of intravenous (iv) iron and erythropoiesis-stimulating agents (ESAs). We provide detailed analyses of changes in iron/hematologic parameters and iv iron/ESA use at time points throughout the active control period of a phase 3 international randomized clinical trial. In all, 441 subjects were randomized (292 to FC and 149 to sevelamer carbonate and/or calcium acetate [active control (AC)]) and followed for 52 weeks. Subjects on FC had increased ferritin and transferrin saturation (TSAT) levels compared with subjects on AC by week 12 (change in ferritin, 114.1±29.35 ng/ml; P

Medical Subject Headings

Administration, Intravenous; Anemia; Drug Therapy, Combination; Female; Ferric Compounds; Hematinics; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged

PubMed ID

25736045

Volume

26

Issue

10

First Page

2578

Last Page

2587

Share

COinS